Why So Few New Cardiovascular Drugs Translate to the Clinics

Stephen F. Vatner

There are multiple reasons for the failure to successfully translate new drugs to the clinics. One reason, noted by others, is the lack of reproducibility of studies and the problems with accuracy and rigor. However, another reason for translational failure has not been emphasized by others, that is, the lack of state-of-the-art cardiovascular measurements, because of effects of anesthesia, lack of direct measurements of cardiovascular function, and problems of species differences. In part, this is because of the impact of molecular medicine on traditional physiology, which not only affects priority for publication in top-tier journals, but also funding priorities for National Institutes of Health (NIH) study sections, resulting in the closure of almost all cardiovascular physiology laboratories, leaving the cardiovascular physiology in many molecular publications to incidental data that are not peer-reviewed and in many cases are inaccurate. It is the plea of this Viewpoint to correct this deficiency in expertise in our scientific community, a project with no simple solutions.

It is widely recognized that relatively few cardiovascular therapeutic modalities are emerging from the plethora of studies in genetically altered mouse models over the past quarter century, for example, the success rate for new drug development projects in Phase II trials fell from 28% to 18%. The most popular explanation for this decline has been the irreproducibility of data, in that only in 20% to 25% of projects repeated in industry were the data completely in line with what was in the literature, often because published data were incorrect. The current Viewpoint offers a novel reason for failure of translation, that is, the difficulties, limitations, and errors in studying cardiovascular physiology in the 21st century.

The goal of this Viewpoint is not to dwell on papers with false or inaccurate data, but rather to offer other reasons for problems in data that lead to failure of clinical translation. Because the numbers of citations are limited by the Viewpoint format and because of the sensitivity of pointing out errors in other papers or errors in judgment of the pharmaceutical industry, no names of authors with incorrect data or names of complicit institutions will be identified.

Data Fraud and Institutional Complicity

One of the most egregious examples occurred when I was the Editor of Circulation Research, where the authors had plagiarized another paper on the effects of a circulating hormone word-for-word and substituted only the name of the circulating hormone throughout the paper and, obviously, also changed the authors names and the university from which it came. Another example involved manufactured data; the authors never responded to this criticism and just published it in another journal. It turns out that the problem of rejecting a paper, even if the data are false, does not prevent the data from being published in another journal. Another point is that institutions, such as the Universities involved, the American Heart Association, and NIH, were hesitant to pursue either of these issues.

Species Differences

Species differences is one reason why drugs are not being successfully translated to patients. There is an overwhelming reliance on studies in rodents, with rare studies being conducted in large mammalian models. Most importantly, the fewest studies have been in primates, even though their physiology is closest to humans. For example, primates, but not rodents, go through menopause, and for research on aging, it is difficult to extrapolate the rodent’s 2- to 4-year life span to that of a human, whereas monkeys can live ≤30 to 40 years. However, rodents remain the overwhelmingly favorite model for cardiovascular research. The reasons for this are manifold, ranging from prohibitive costs for large-animal research, excessive regulatory restrictions, to lack of experience with large-animal research to potentially the most important reason that the vast majority of research that is being approved for funding by NIH involves genetically altered mouse models, and therefore, these models are studied most extensively.

An example of species difference is that of beta 3-adrenergic receptor stimulation. About 20 years ago, there was considerable interest in translating the exciting basic research to the clinics, with several multimillion-dollar clinical trials failing, which could have been because of species differences. Our laboratory had published on the efficacy of beta 3 stimulation in rodents, and even dogs, but had failed to demonstrate efficacy in nonhuman primates. Even though after one of the coauthors took a position at a major pharmaceutical company and tried to explain the negative results, the company went forward with the clinical trials...
and also published a paper in nonhuman primates that purportedly showed the beneficial vasodilator actions of the drug. That paper used facial flushing as their data for peripheral vasodilation, rather than direct measurements of arterial pressure and regional blood flows.

**Effects of Anesthesia**

The overwhelming number of cardiovascular research studies performed are in acutely prepared or anesthetized animal models, despite the fact that there are profound direct effects of anesthesia on cardiovascular function, but more importantly, anesthesia alters autonomic cardiovascular control and secondarily alters responses to common interventions, such as drugs. Thus, it is not difficult to imagine how anesthesia may modify results and also in understanding the effects of drugs for translation to the clinics. A recent example occurred with a new drug that increases sarcomere contractility in the heart, a novel mechanism to improve cardiac performance. Studies in chronically instrumented, conscious animals with heart failure found that this drug was superior to sympathomimetic amines because it improved myocardial function without an increase in myocardial oxygen consumption (MVO₂). Different results were reported in anesthetized animals, where the drug no longer had the salutary action on protecting MVO₂, which is most critical for success of any inotropic agents in patients with heart failure.

**Lack of Physiological Expertise**

A major problem for the accuracy of cardiovascular measurements relates to lack of ability to use direct and continuous measurements of left ventricular dimensions, pressures, and arterial pressure and regional blood flows. There are only a handful of laboratories in the world where this expertise still exists. As noted earlier, most laboratories, particularly those studying mice, rely on indirect techniques, for example, echocardiography, to assess left ventricular function. This technique generally requires anesthesia, which can affect circulatory dynamics markedly as already discussed. Another limitation is that these studies generally rely solely on measurements of left ventricular ejection fraction or fractional shortening to assess left ventricular function, disregarding effects of preload and afterload that can affect these measurements significantly. Furthermore, stroke volume calculated from published echo data of diameters often is opposite to the conclusions of these papers, based only on fractional shortening.

**Inadvertent Negative Impact of the Era of Molecular Biology on Traditional Physiology**

Sometimes major advances have unintended consequences. Such is the case for the advances in cardiovascular research induced by the molecular biology revolution a quarter century ago, resulting in the decline of physiology laboratories because of the inability for them to compete for publication space in top-tier journals and for the limited NIH funding. I was complicit by transforming the major emphasis of Circulation Research from physiology to molecular biology.

**Wishful Thinking**

Another reason for failure of drug development is wishful thinking, that is, assuming a mechanism from indirect data or based on data from inadequate measurements. One example is apoptosis. Since its discovery in 1972 as a novel mediator of cell death, studies of apoptosis mushroomed. One reason for the explosion of studies relates to the ease of measuring apoptosis by the TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) technique, which does not require extensive training to learn. When increased apoptosis was correlated with heart failure, this mechanism became widely recognized as a major factor in mediating heart failure. This conclusion was based on the assumption that apoptosis only occurred in myocytes in the heart, and the resulting loss of myocytes is an important mechanism for the development of heart failure, but was never documented. Because over 70% of cells in the heart are nonmyocytes, it would be easy to exaggerate the importance of apoptosis on cardiac function, if its occurrence was in nonmyocytes, which has been recently documented.

Another example is Hibernating Myocardium, a complex syndrome, which refers to severely and chronically depressed myocardial function, which gradually recovers, but not always completely, after revascularization. Because acute reduction in blood flow reduces myocardial function, it was assumed that blood flow was severely reduced to the dysfunctional myocardium in patients with chronic coronary artery disease. However, these studies did not measure blood flow to the hibernating myocardium. Our studies in chronically instrumented conscious pigs with chronic myocardial ischemia, supported by studies in patients with hibernating myocardium, where blood flow was also actually measured, found that blood flow was not severely depressed in the myocardium that eventually recovered after revascularization and that the reduced function resembled that which was described originally for stunned myocardium.

A third example comes from stem cell therapy, a major focus of cardiovascular research supported by the NIH and the pharmaceutical industry over the past 2 decades. Everyone had wished for successful translation of this breakthrough technology to patients with chronic coronary artery disease. The results have been disappointing, and a recent article by Rosen et al summarizes the multifactorial reasons for the failure, which include errors in infarct zone assessment and need to retract papers, based on wishful thinking.

It is interesting to note that these problems are not limited to cardiovascular research but are also noted in cancer research and even political science. One of the most highly cited political science articles recently concluded that politically conservative individuals have higher Psychotocism scores, which relate to less highly desirable socioeconomic traits, with the reverse for liberals. Unfortunately, it was pointed out to the authors that they made a simple mistake and reversed the codes for conservative and liberal data and then had to print a retraction.

**Shifting Baselines**

A major problem leading to irreproducibility of data is the wide variance of baseline measurements in the same animal model with the same intervention. One example is infarct/
area-at-risk measurements in mouse wild-type models of the same strain and time for coronary occlusion and reperfusion, ranging from 15% to 67% in papers from different laboratories. More disturbing is when the same laboratory reports in different publications markedly different baseline infarct size in the wild-type mice, differing from 15% when the transgenic model is supposed to show increase to as high as 40% in the wild-type, when the transgenic is supposed to show a decrease in infarct size.

**Power of the Purse**

Many laboratories depend on financial support from the pharmaceutical industry. It is understandable that the industry wants to see favorable effects of their drugs, and it is widely recognized that they prefer to support laboratories for their studies, where the likelihood of positive results is more predictable. The lure of funding is an important reason why data can be biased and irreproducible. Two experiences from our laboratory support this concept. Our laboratory was supported for several years by a company involved in developing calcium channel blockers until the support was cut off after we found in chronically instrumented conscious baboons that there was no reduction in infarct size with these drugs.14 Another example is the support our laboratory received from the American Medical Association to study the effects of nicotine on the coronary circulation, when we found in 1975 that it induced coronary vasodilation,15 but later, in 1984, when we found that nicotine also caused reflex vasoconstriction,16 the American Medical Association no longer funded our laboratory; maybe to no surprise because the funds were given to the American Medical Association from the cigarette industry.

It is not only industry funding that can bias research reporting, but also the power of NIH funding. It would also be important to determine how many studies supported by NIH published irreproducible results. A simple way of examining this issue would be to examine the NIH funding supporting all those retracted papers, which were published in the top-tier journals. It does not require much imagination to figure out the link between publication in journals of the highest impact factor and future NIH funding and the link to Publish or Perish.

**Publication in Prestigious Journals**

Randy Schekman, the Nobel Laureate, recently published a paper on why he does not publish in prestige journals, indicating that the editors are more interested in flashy articles, which sometimes are not based on solid data.17 This point is substantiated by the number of articles that have been retracted from these prestigious journals.1

**Summary**

In conclusion, this Viewpoint has put forth multiple new reasons for the failure to successfully translate new drugs to the clinics from the bench (Figure). Several of the concepts proposed have also been noted by others, for example, the lack of reproducibility of studies and the problems with accuracy and rigor.1 However, one of the reasons for translational failure has not been emphasized by others, that is, the lack of state-of-the-art cardiovascular measurements. Several reasons have been proposed in this viewpoint, for example, effects of anesthesia, lack of direct measurements of cardiovascular function, and problems of species differences. One final point needs to be mentioned and that is the impact of molecular medicine on traditional physiology. The priorities of prestigious journals and NIH have moved away from traditional physiology over the past quarter century, resulting in lack of state-of-the-art physiology laboratories, leaving the cardiovascular physiology in many molecular publications to incidental data that are not peer-reviewed and are in many

---

**Figure.** This figure summarizes the reasons for failed clinical translation and irreproducibility of results. Problems with accuracy and rigor of data collection have been noted by others. This figure also summarizes other reasons for failure of clinical translation, not noted by others, eg, the lack of state-of-the-art cardiovascular measurements, effects of anesthesia, lack of direct measurements of cardiovascular function, and problems of species differences. In addition, many studies are based on existing concepts not supported by data, and are biased towards what attracts industry and NIH funding.
cases inaccurate. It is the plea of this Viewpoint to correct this deficiency in expertise in our scientific community, a project with no simple solutions.

Sources of Funding
This study was supported by National Institutes of Health grants R01HL102472, T32HL069752, R01HL093481, R01HL106511, R01HL124282, and R01HL130848.

Disclosures
None.

References

Key Words: academic fraud ■ cardiovascular physiology ■ pharmacology
Why So Few New Cardiovascular Drugs Translate to the Clinics
Stephen F. Vatner

Circ Res. 2016;119:714-717
doi: 10.1161/CIRCRESAHA.116.309512
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/119/6/714

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/